Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Sheehan

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Journal of Medicinal Chemistry|May 15, 2009
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitorsAllen J Duplantier, Stacey L Becker, Michael J Bohanon, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Journal of Medicinal Chemistry|May 15, 2009
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitorsAllen J Duplantier, Stacey L Becker, Michael J Bohanon, et al.
Pageof 4